Date | Price Target | Rating | Analyst |
---|---|---|---|
5/30/2024 | $156.00 | Buy | Goldman |
4/12/2024 | $163.00 | Outperform | BMO Capital Markets |
1/23/2024 | $120.00 | Overweight | Morgan Stanley |
1/16/2024 | Neutral | UBS | |
12/1/2023 | $120.00 | Overweight | Cantor Fitzgerald |
10/2/2023 | $110.00 | Buy | Argus |
7/14/2023 | Buy | HSBC Securities | |
7/15/2022 | Equal-Weight → Overweight | Morgan Stanley |
Goldman initiated coverage of Novo Nordisk A/S with a rating of Buy and set a new price target of $156.00
BMO Capital Markets initiated coverage of Novo Nordisk A/S with a rating of Outperform and set a new price target of $163.00
Morgan Stanley initiated coverage of Novo Nordisk A/S with a rating of Overweight and set a new price target of $120.00
6-K - NOVO NORDISK A S (0000353278) (Filer)
6-K - NOVO NORDISK A S (0000353278) (Filer)
6-K - NOVO NORDISK A S (0000353278) (Filer)
Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 62% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $155,555 and 5, calls, for a total amount of $255,360. What's The Price Target? Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $175.0 for Novo Nordisk during the past quarter. Analyzing Volume & Open Interest Assessing
The National Health Service (NHS) has prescribed Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy far less often than anticipated, struggling with a shortage of weight management clinics required to distribute the popular treatment. Since its launch, the drug has been prescribed just 3,300 times, significantly below the 13,500 patients expected to receive it in its first year, according to a Financial Times analysis of NHS England data. Demand for Wegovy is set to increase following the Medicines and Healthcare Products Regulatory Agency’s (MHRA) approval for its use in reducing the risk of serious heart problems or strokes in overweight and obese adults. Despite this, the drug
Designed to celebrate diverse, unique portrayals of individuals who partner with their healthcare professional to change the course of their weight-management journey, while educating on the clinical data of Wegovy®Reflects the power of personal journeys to address stigma, and the importance of us all working together to address excess weight and treat obesityPLAINSBORO, N.J., June 3, 2024 /PRNewswire/ -- Novo Nordisk today launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® (semaglutide) 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don't have to manage their weight alone
Wegovy® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term weight management1The approval is based on the results of SELECT, the largest cardiovascular outcomes trial ever completed for people with obesity and known heart disease2 PLAINSBORO, N.J., March 8, 2024 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with eithe
NetworkNewsWire Editorial Coverage NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of t
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr
NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees. "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We lo
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,